Single-cell analysis

One Biosciences Welcomes Dr. Scott Braunstein and Dr. Vincent Miller to its Board of Directors

Retrieved on: 
Wednesday, March 27, 2024
Constellation, Single-cell analysis, Lung cancer, EGFR, Health, Biotechnology, Rachel Haurwitz, New Jersey Medical School, Foundation Medicine, Cornell University, University, Knowledge, American Cancer Society, Research, Esperion Therapeutics, Cancer, A.I, Medicine, Summit Health, Esperies, Therapy, Drug development, Partner, MorphoSys, JPMorgan Chase, Thomas Jefferson University Hospital

to identify a new generation of precision medicine targets and develop new treatments, today announced the appointments of Dr. Scott Braunstein, and Dr. Vincent Miller, to its Board of Directors.

Key Points: 
  • to identify a new generation of precision medicine targets and develop new treatments, today announced the appointments of Dr. Scott Braunstein, and Dr. Vincent Miller, to its Board of Directors.
  • Our proprietary discovery engine has identified its first promising targets, and we are preparing to start drug development activities in 2025.
  • Bolstering our Board with such seasoned leaders will be a key factor to success.”
    Dr. Scott Braunstein brings over 30 years of knowledge and experience gained in the biotechnology, pharmaceutical, and biotech portfolio management industries.
  • Dr. Braunstein is currently on the board at Trevena and Caribou Biosciences.

Relation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm

Retrieved on: 
Thursday, March 14, 2024
ARK, Single-cell analysis, Genomics, Gene, Cell, Disease, Drug discovery, General partnership, Patient, Tissue, Khosla Ventures, AI, Biology, Therapy, Osteoporosis, Machine learning, Ark Invest, NVIDIA, Relation, Pharmaceutical industry

Relation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm

Key Points: 
  • Relation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm
    London, March 2024 – Relation Therapeutics, a biotechnology company at the forefront of leveraging computational and experimental approaches to drug discovery, today announced $35 million in new seed financing, bringing its total seed fundraise to $60 million.
  • David Roblin, CEO of Relation Therapeutics, said: "This financing is a significant milestone for Relation Therapeutics and underscores the confidence our investors have in our innovative approach to drug discovery and development.
  • Our technology platform, uniquely integrated with deep R&D expertise, places us in an outstanding position to transform drug discovery.
  • “We see Relation as a leader in the emerging techbio economy,” said Jason Pontin, General Partner at DCVC, who sits on Relation’s board.

Takara Bio transforms single-cell landscape with new large-scale NGS profiling system for oncology biomarker discovery

Retrieved on: 
Tuesday, April 2, 2024
Oncology, Health, Health Technology, Genetics, Research, Science, Biotechnology, Single-cell analysis, Cell, NGS, Biomarker, RNA, ABRF, Messenger, Head, AACR, Chemistry, Neoplasm, Booth, RNA-Seq, WGA, SNV, Annual general meeting, CNV, Vaccine

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the Shasta™ Single-Cell System, an automated, high-throughput NGS solution with well-validated chemistries and intuitive bioinformatics tools that enables novel biomarker discovery for oncology research.

Key Points: 
  • Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the Shasta™ Single-Cell System, an automated, high-throughput NGS solution with well-validated chemistries and intuitive bioinformatics tools that enables novel biomarker discovery for oncology research.
  • Existing whole-genome amplification (WGA) technologies currently process 96–384 single cells per plate; the Shasta system increases WGA throughput to 1,500 cells per run.
  • In March, Takara Bio USA delivered instruments and NGS kits to early-access users, who have started producing results with the system.
  • We have two other projects in the lab where we want to do a full set of profiling of our entire model system.

BioSkryb Genomics to Present Novel Research on Tumor Heterogeneity at American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Thursday, March 28, 2024
Oncology, Health, Health Technology, Genetics, Research, Science, Biotechnology, Single-cell analysis, Disease, Transcriptome, Malignancy, Neoplasm, DNA, Genome, Workflow, AACR, Doctor of Philosophy, Phenotype, Genomics, SNV, Ageing, CNV, Mobile phone

BioSkryb Genomics , a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer Research® (AACR) Annual Meeting 2024 on April 5-10, 2024 in San Diego, CA.

Key Points: 
  • BioSkryb Genomics , a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer Research® (AACR) Annual Meeting 2024 on April 5-10, 2024 in San Diego, CA.
  • “Tumor heterogeneity is a key challenge for researchers in the cancer research field.
  • As tumors evolve, subclones emerge with mutations that convey adaptive phenotypes, including resistance to therapies,” said Suresh Pisharody, CEO of BioSkryb.
  • “Our next generation single-cell technology gives scientists the tools to better understand the way tumors evolve with a comprehensive, scalable, and streamlined workflow.

Fluent Biosciences announces early access availability of transformative direct-guide capture for single cell analysis for complex CRISPR screening in Particle-templated Instant Partitions (PIPseq-CRISPR)

Retrieved on: 
Thursday, March 21, 2024
Single-cell analysis, Stanford University, Doctor of Philosophy, Fluency, Cell, Messenger, CRISPR

WATERTOWN, Mass., March 21, 2024 /PRNewswire/ -- Fluent BioSciences, a life sciences company focused on making single-cell analysis simple and accessible to every researcher, announces early access availability of new kits and reagents for direct CRISPR guide capture in particle templated instant partitions (PIPseq-CRISPR).

Key Points: 
  • WATERTOWN, Mass., March 21, 2024 /PRNewswire/ -- Fluent BioSciences, a life sciences company focused on making single-cell analysis simple and accessible to every researcher, announces early access availability of new kits and reagents for direct CRISPR guide capture in particle templated instant partitions (PIPseq-CRISPR).
  • The PIPseq platform provides an instrument and microfluidics-free approach for single cell analysis, eliminating barriers to accessibility and program costs that limit routine application of high-throughout single cell analysis.
  • These early access kits allow for universal capture of CRISPR guide-RNA in addition to 3' mRNA capture from single-cell suspensions, enabling complex perturbation screening at unprecedented scale and cost.
  • For more information or consideration for early access evaluation of PIPseq-CRISPR reagents, please contact us [email protected] .

Fluent BioSciences awarded NIH SBIR grant to commercialize low-cost million-cell transcriptome profiling kits powered by Ultima Genomics sequencing, prototype kits now shipping

Retrieved on: 
Thursday, March 21, 2024
Single-cell analysis, Stem cell, Growth, Cell, WUSTL, Associate, Partnership, Microfluidics, SBIR, Fluency, NIGMS, Genomics, CRISPR, CSO, Fine chemical

This funding will support the commercialization of million-cell analysis kits enabled by low-cost, high-capacity sequencing by Ultima Genomics.

Key Points: 
  • This funding will support the commercialization of million-cell analysis kits enabled by low-cost, high-capacity sequencing by Ultima Genomics.
  • Ultima Genomics sequencing of the prototype million-cell PIPseq data revealed clonal lineage trees with restriction of specific cell reprogramming fates.
  • "The collaboration between Fluent BioSciences and Ultima represents a remarkable synergy in pushing the boundaries of single-cell analysis," said Brian McKernan, CEO of Fluent BioSciences.
  • To learn more about Fluent BioSciences' million-cell PIPseq prototype kits and how they can empower high-throughput single-cell profiling, please contact [email protected] .

Factorial Biotechnologies Unveils Mosaic™: Enabling Single-Cell Analysis Across All Omic Applications

Retrieved on: 
Monday, February 5, 2024
SAN, Life, Workflow, RNA, Research, DNA, Innovation system, Biomarker, Single-cell analysis, Disease, NGS, Medicine, Health, Library

Mosaic transcends limitations by offering the broadest content single-cell platform, enabling single-cell resolution across a wide range of NGS applications.

Key Points: 
  • Mosaic transcends limitations by offering the broadest content single-cell platform, enabling single-cell resolution across a wide range of NGS applications.
  • Factorial opens early access program for researchers interested in single-cell DNA sequencing and multi-omic applications.
  • Recognizing the immense demand in this disruptive technology, Factorial is extending an early access program for researchers interested in single-cell DNA sequencing and multi-omic applications.
  • "Mosaic represents a pivotal moment in single-cell analysis," states John Wells, founder and CEO of Factorial Biotechnologies.

BioSkryb Genomics to Highlight Power of Next Generation Single-Cell Technology at AGBT 2024

Retrieved on: 
Tuesday, January 30, 2024
Research, Technology, Other Technology, Other Health, Biotechnology, General Health, Health, Science, Oncology, Other Science, Genomics, Product management, Mosaic, Workflow, B cell, DNA, Transcriptome, Single-cell analysis, ETH Zurich, CNV, Exome, PTA, SNV, Leukemia

As a Bronze Sponsor, BioSkryb will also host a workshop and networking event at the meeting.

Key Points: 
  • As a Bronze Sponsor, BioSkryb will also host a workshop and networking event at the meeting.
  • “Our industry-first next generation single-cell technology offers the most comprehensive view of the integrated genome, transcriptome, and targeted proteins from each cell in a single workflow, and we are thrilled to highlight novel applications of our platforms at AGBT,” said Suresh Pisharody, CEO, BioSkryb.
  • BioSkryb’s events at AGBT 2024 are as follows:
    Jay A.A. West, Ph.D., Co-Founder & CTO, BioSkryb Genomics advances multiomics and highly accurate single-cell analysis with the next generation of single-cell technology.
  • Join BioSkryb and AGBT attendees to mingle with genomics and multiomics thought leaders over top-shelf bourbon selections and gourmet bacon-themed appetizers.

Advaita Bio awarded $1.7 million NIH study to pioneer platform for the analysis of single-cell data

Retrieved on: 
Tuesday, January 30, 2024
ANN, Research, Single-cell analysis, Life, Collection, RNA-Seq, Knowledge, Science, Computer, Gene, Advaita Vedanta, Single-nucleotide polymorphism, Principal investigator, Software, NIH, Auburn University, DVM, Protein, Doctor of Philosophy, Bangladesh Technical Education Board

ANN ARBOR, Mich., Jan. 30, 2024 /PRNewswire-PRWeb/ -- Advaita Bio was awarded $1.7 million from the National Institute of Health (NIH) to develop a new platform for the analysis of single-cell data. AdvaitaBio is the leader in the interpretation of high-throughput biomedical data including variant interpretation, pathway analysis, disease subtype discovery, single cell analysis, and integration across multiple data types. This research will develop advanced methods for the analysis of single cell and spatial genomics and transcriptomics data.

Key Points: 
  • ANN ARBOR, Mich., Jan. 30, 2024 /PRNewswire-PRWeb/ -- Advaita Bio was awarded $1.7 million from the National Institute of Health (NIH) to develop a new platform for the analysis of single-cell data.
  • AdvaitaBio is the leader in the interpretation of high-throughput biomedical data including variant interpretation, pathway analysis, disease subtype discovery, single cell analysis, and integration across multiple data types.
  • This research will develop advanced methods for the analysis of single cell and spatial genomics and transcriptomics data.
  • Advaita's Life Scientist and Principal Investigator, Cristiana Iosef, DVM, PhD, explains, "The world of single cell analysis is currently a jungle.

BD, Hamilton Collaborate to Standardize Single-Cell Multiomics Experiments Using Robotics

Retrieved on: 
Tuesday, January 23, 2024
NGS, Library, Health, DNA, Multiomics, BDX, Single-cell analysis, Disease, Automation, Cell, Computer data storage

FRANKLIN LAKES, N.J., Jan. 23, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced a collaboration agreement with Hamilton, a leading global manufacturer of laboratory automation technology, to develop automated applications together with robotics-compatible reagent kits to enable greater standardization and reduced human error when conducting large-scale single-cell multiomics experiments.

Key Points: 
  • The combination will automate steps, including pipetting and thermal cycling, to produce DNA samples or "libraries" that are ready for genetic sequencing.
  • In single-cell multiomics experiments, constructing libraries of fragmented genetic information that can be read by sequencing instruments is an essential first step before next-generation sequencing (NGS) can be performed and insights from cells can be gathered.
  • As more researchers adopt the rapidly evolving and important approach of single-cell multiomics, we believe that having automated solutions for high-throughput experiments will serve to accelerate their potentially life-changing discoveries."
  • The BD Rhapsody™ Single-Cell Analysis Library Preparation Reagent Kits and Hamilton Microlab® NGS STAR™ applications will be developed and released in phases starting in 2024.